Indivior Pharmaceuticals (INDV) Total Non-Current Liabilities (2021 - 2026)

Indivior Pharmaceuticals' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 19.66% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (down 19.66% YoY), while the FY2025 annual figure was $1.3 billion, down 21.73% from the prior year.
• Total Non-Current Liabilities was $1.3 billion for Q1 2026 at Indivior Pharmaceuticals, up from $1.3 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $1.7 billion in Q2 2025 to a low of $649.0 million in Q4 2023.
• Historically, Total Non-Current Liabilities has averaged $1.3 billion across 5 years, with a median of $1.5 billion in 2025.
• The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities soared 151.77% in 2024, then declined 21.73% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $699.0 million in 2022, then retreated by 7.15% to $649.0 million in 2023, then surged by 151.77% to $1.6 billion in 2024, then slipped by 21.73% to $1.3 billion in 2025, then rose by 3.21% to $1.3 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.